These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
418 related articles for article (PubMed ID: 18479179)
1. Current and future antiretroviral treatment options in paediatric HIV infection. Giaquinto C; Morelli E; Fregonese F; Rampon O; Penazzato M; de Rossi A; D'Elia R Clin Drug Investig; 2008; 28(6):375-97. PubMed ID: 18479179 [TBL] [Abstract][Full Text] [Related]
2. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774 [TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
4. Nucleoside and nucleotide reverse transcriptase inhibitors in children. Giaquinto C; Rampon O; Penazzato M; Fregonese F; De Rossi A; D'Elia R Clin Drug Investig; 2007; 27(8):509-31. PubMed ID: 17638393 [TBL] [Abstract][Full Text] [Related]
5. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608 [TBL] [Abstract][Full Text] [Related]
6. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC; Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787 [TBL] [Abstract][Full Text] [Related]
7. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261 [TBL] [Abstract][Full Text] [Related]
8. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors. Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J; Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673 [TBL] [Abstract][Full Text] [Related]
9. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008 [TBL] [Abstract][Full Text] [Related]
10. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Aboud M; Kaplan R; Lombaard J; Zhang F; Hidalgo JA; Mamedova E; Losso MH; Chetchotisakd P; Brites C; Sievers J; Brown D; Hopking J; Underwood M; Nascimento MC; Punekar Y; Gartland M; Smith K Lancet Infect Dis; 2019 Mar; 19(3):253-264. PubMed ID: 30732940 [TBL] [Abstract][Full Text] [Related]
11. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA; Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068 [TBL] [Abstract][Full Text] [Related]